Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients

Background. Nonalcoholic fatty liver disease (NAFLD) is a rising indication for liver transplantation (LT). Identification of NAFLD recurrence and those at risk for more progressive disease after LT remains elusive as the diagnosis requires biopsy, which is invasive and impractical for serial monito...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christopher J. Mowry, MD, Cristina Alonso, PhD, Marta Iruarrizaga-Lejarreta, PhD, Pablo Ortiz, MD, PhD, Josh Levitsky, MD, MS, Mary Rinella, MD
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer 2021
Materias:	Surgery RD1-811
Acceso en línea:	https://doaj.org/article/7d381d77ca3448e398a9f05fef8fee10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d381d77ca3448e398a9f05fef8fee10
record_format	dspace
spelling	oai:doaj.org-article:7d381d77ca3448e398a9f05fef8fee102021-11-25T07:59:57ZUtility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients2373-873110.1097/TXD.0000000000001227https://doaj.org/article/7d381d77ca3448e398a9f05fef8fee102021-12-01T00:00:00Zhttp://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001227https://doaj.org/toc/2373-8731Background. Nonalcoholic fatty liver disease (NAFLD) is a rising indication for liver transplantation (LT). Identification of NAFLD recurrence and those at risk for more progressive disease after LT remains elusive as the diagnosis requires biopsy, which is invasive and impractical for serial monitoring. We therefore aimed to identify metabolites in the blood associated with recurrent NAFLD that could potentially be used for detection and monitoring. Methods. This cross-sectional pilot study included 37 LT recipients who underwent simultaneous liver biopsy and plasma collection for metabolomic analysis. Metabolic profiles were compared between patients with recurrent NAFLD, normal liver (negative control), and acute rejection (rejection control). Results. Univariate analysis revealed 14 metabolites that were significantly altered in patients with recurrence of NAFLD compared with negative controls and 19 compared with rejection controls (P < 0.05). In addition, metabolomic profiling identified 16 metabolites that distinguished nonalcoholic fatty liver versus nonalcoholic steatohepatitis. Metabolite class trends among patients with recurrent NAFLD following LT were consistent with prior metabolomics data in patients with NAFLD in the non-LT setting. Conclusions. In conclusion, we identified candidate metabolites that could be used in the clinical setting to noninvasively identify recurrent NAFLD and differentiate NAFL from the more progressive nonalcoholic steatohepatitis. Further investigation with a larger sample size is warranted to validate these results.Christopher J. Mowry, MDCristina Alonso, PhDMarta Iruarrizaga-Lejarreta, PhDPablo Ortiz, MD, PhDJosh Levitsky, MD, MSMary Rinella, MDWolters KluwerarticleSurgeryRD1-811ENTransplantation Direct, Vol 7, Iss 12, p e784 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Surgery RD1-811
spellingShingle	Surgery RD1-811 Christopher J. Mowry, MD Cristina Alonso, PhD Marta Iruarrizaga-Lejarreta, PhD Pablo Ortiz, MD, PhD Josh Levitsky, MD, MS Mary Rinella, MD Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
description	Background. Nonalcoholic fatty liver disease (NAFLD) is a rising indication for liver transplantation (LT). Identification of NAFLD recurrence and those at risk for more progressive disease after LT remains elusive as the diagnosis requires biopsy, which is invasive and impractical for serial monitoring. We therefore aimed to identify metabolites in the blood associated with recurrent NAFLD that could potentially be used for detection and monitoring. Methods. This cross-sectional pilot study included 37 LT recipients who underwent simultaneous liver biopsy and plasma collection for metabolomic analysis. Metabolic profiles were compared between patients with recurrent NAFLD, normal liver (negative control), and acute rejection (rejection control). Results. Univariate analysis revealed 14 metabolites that were significantly altered in patients with recurrence of NAFLD compared with negative controls and 19 compared with rejection controls (P < 0.05). In addition, metabolomic profiling identified 16 metabolites that distinguished nonalcoholic fatty liver versus nonalcoholic steatohepatitis. Metabolite class trends among patients with recurrent NAFLD following LT were consistent with prior metabolomics data in patients with NAFLD in the non-LT setting. Conclusions. In conclusion, we identified candidate metabolites that could be used in the clinical setting to noninvasively identify recurrent NAFLD and differentiate NAFL from the more progressive nonalcoholic steatohepatitis. Further investigation with a larger sample size is warranted to validate these results.
format	article
author	Christopher J. Mowry, MD Cristina Alonso, PhD Marta Iruarrizaga-Lejarreta, PhD Pablo Ortiz, MD, PhD Josh Levitsky, MD, MS Mary Rinella, MD
author_facet	Christopher J. Mowry, MD Cristina Alonso, PhD Marta Iruarrizaga-Lejarreta, PhD Pablo Ortiz, MD, PhD Josh Levitsky, MD, MS Mary Rinella, MD
author_sort	Christopher J. Mowry, MD
title	Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
title_short	Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
title_full	Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
title_fullStr	Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
title_full_unstemmed	Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
title_sort	utility of metabolomic biomarkers to identify nonalcoholic fatty liver disease in liver transplant recipients
publisher	Wolters Kluwer
publishDate	2021
url	https://doaj.org/article/7d381d77ca3448e398a9f05fef8fee10
work_keys_str_mv	AT christopherjmowrymd utilityofmetabolomicbiomarkerstoidentifynonalcoholicfattyliverdiseaseinlivertransplantrecipients AT cristinaalonsophd utilityofmetabolomicbiomarkerstoidentifynonalcoholicfattyliverdiseaseinlivertransplantrecipients AT martairuarrizagalejarretaphd utilityofmetabolomicbiomarkerstoidentifynonalcoholicfattyliverdiseaseinlivertransplantrecipients AT pabloortizmdphd utilityofmetabolomicbiomarkerstoidentifynonalcoholicfattyliverdiseaseinlivertransplantrecipients AT joshlevitskymdms utilityofmetabolomicbiomarkerstoidentifynonalcoholicfattyliverdiseaseinlivertransplantrecipients AT maryrinellamd utilityofmetabolomicbiomarkerstoidentifynonalcoholicfattyliverdiseaseinlivertransplantrecipients
_version_	1718413567712034816

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients

Ejemplares similares